Health Infrastructure is supporting the NSW Office of the Chief Scientist and Engineer in building a new RNA Research and Pilot Manufacturing Facility that will enable research, development and production of a broad spectrum of RNA technologies locally.
OVERVIEW
The new facility will conduct small-scale production of messenger RNA (mRNA), Plasmid DNA (pDNA) and lipid nanoparticles (LNP) encapsulation at a scale which will enable clinical trials of new therapeutics.
Viruses, cancers, genetic diseases and many other health-related issues are potentially treatable with RNA technologies.
The new facility will be located in the Connect Innovation Precinct at Macquarie University and operated by Aurora Biosynthetics, part of a global therapeutics company. It will include laboratories and other support spaces and will develop and produce a wide range of new and existing RNA therapeutics. Therapies will include vaccines as well as treatments for rare diseases in both people and animals.
The NSW Government has committed $96 million to build the RNA Research and Pilot Manufacturing Facility.
A further $119 million has been announced over 10 years for RNA research and development initiatives.
BENEFITS
The project will:
- Be the first opportunity for RNA research and development to be tested and developed locally, across the broad spectrum of RNA technology, reducing Australia’s reliance on international supply
- Provide Australian patients with faster access to new and innovative RNA therapeutics to treat diseases such as cancer and rare genetic diseases
- Attract global industry investment to Australia, foster local jobs and skills and secure domestic-market access to future therapeutics
- Be central to NSW’s thriving RNA research and development ecosystem, surrounded by medical and research facilities, existing infrastructure, and world-leading RNA and cell and gene therapy expertise
- Boost innovation and technology in NSW, centralise RNA knowledge and expertise, create highly skilled jobs, and help NSW become a global leader in RNA research and production
- Capitalise on NSW’s competitive advantage by translating its strengths in research and development into a sustainable commercial pipeline of RNA therapeutics and products.
SCOPE
The project includes:
- New manufacturing facility with a floor area of around 4,500sqm
- Design, equipment and fit-out of facility to produce small scale RNA-based products for clinical trials.
For more information read:
RELATED DOCUMENTS
A24a(i): Approved Plans
A24a(ii): Current Statutory Approvals
A24a(iii): Approved Strategies, Plans and Programs
A24a(v): Summary of Monitoring Results
A24a(viii): Complaints Register
A24a(ix): Audit Report and Applicants Response
B4: External Walls and Cladding
B26 Construction Worker Transportation Strategy
A24a(viii): Contact Details to enquire about the project
If you'd like to ask a question, provide feedback or learn more about the RNA project, please contact our team at [email protected].
To access further planning documentation for this project, please visit the NSW Planning Portal.